Summit Therapeutics Inc. Common Stock (SMMT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Summit Therapeutics Inc. Common Stock (SMMT)
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Key Insights
Critical company metrics and information
Share Price
$18.54Market Cap
$13.67 BillionTotal Outstanding Shares
737.45 Million SharesTotal Employees
105Dividend
No dividendIPO Date
March 5, 2015SIC Description
Pharmaceutical PreparationsHomepage
https://www.smmttx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $411.09 Million |
Net Cash Flow From Financing Activities | $411.09 Million |
Net Cash Flow From Investing Activities, Continuing | $-228.25 Million |
Net Cash Flow | $69.94 Million |
Net Cash Flow From Investing Activities | $-228.25 Million |
Net Cash Flow From Operating Activities, Continuing | $-112.89 Million |
Net Cash Flow, Continuing | $69.94 Million |
Net Cash Flow From Operating Activities | $-112.89 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Parent | $-196.68 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Benefits Costs and Expenses | $196.97 Million |
Income/Loss From Continuing Operations Before Tax | $-196.68 Million |
Operating Expenses | $196.88 Million |
Net Income/Loss | $-196.68 Million |
Revenues | $287000.00 |
Nonoperating Income/Loss | $85000.00 |
Income/Loss From Continuing Operations After Tax | $-196.68 Million |
Basic Average Shares | $739.45 Million |
Diluted Average Shares | $739.45 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-196.68 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Earnings Per Share | $0.23 |
Operating Income/Loss | $-196.59 Million |
Diluted Earnings Per Share | $0.23 |
Costs And Expenses | $196.88 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Liabilities | $47.80 Million |
Noncurrent Liabilities | $5.92 Million |
Other Non-current Assets | $12.30 Million |
Assets | $502.85 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity | $437.92 Million |
Accounts Payable | $3.25 Million |
Noncurrent Assets | $12.56 Million |
Liabilities And Equity | $502.85 Million |
Liabilities | $64.93 Million |
Fixed Assets | $265000.00 |
Wages | $7.96 Million |
Current Assets | $490.29 Million |
Equity Attributable To Parent | $437.92 Million |
Current Liabilities | $59.01 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.